Ear, Nose, Mouth and Throat Malignancy DRG Payment Rates

DRG 148 encompasses inpatient admissions for malignancies of the ear, nose, mouth, and throat without Complication or Comorbidity or Major Complication or Comorbidity; it covers primary tumor resections, limited reconstruction, and diagnostic procedures. Accurate classification matters because this Diagnosis-Related Group defines the bundled Medicare reimbursement for uncomplicated head and neck cancer hospitalizations and affects hospital revenue and coding accuracy.

DRG 148 Overview

DRG 148 covers inpatient stays for malignant neoplasms of the ear, nose, mouth, and throat without Complication or Comorbidity or Major Complication or Comorbidity. Typical cases include primary resections, limited reconstructive procedures, and diagnostic interventions for head and neck cancers when no additional acute complicating conditions are present. This Diagnosis-Related Group is important for Medicare payment because it groups clinically similar resource use and establishes the base inpatient reimbursement for these straightforward oncologic admissions. Understanding the clinical scope helps hospitals classify cases for appropriate Medicare Severity Diagnosis-Related Group assignment and payment.

Neoadjuvant and perioperative therapy trials assessing the impact of chemotherapy and/or radiation given before definitive surgery: these studies enroll patients with operable head and neck squamous cell carcinomas of the ear, nose, mouth, and throat who are scheduled for tumor resection and neck dissection. Investigators measure tumor downstaging, margin status, rates of organ-preserving surgery, and perioperative complication rates to determine whether preoperative therapy improves surgical outcomes. Results are relevant to providers and payers because improved downstaging can reduce extent of surgery, length of stay, and downstream costs associated with extensive reconstructions and complications.
Comparative effectiveness studies of surgical approaches and perioperative management for primary resection without major complications: these pragmatic trials or registry analyses compare techniques such as transoral robotic or endoscopic resections versus open approaches, different reconstruction strategies, and enhanced recovery after surgery (ERAS) protocols in patients without major comorbidities. They focus on short-term inpatient outcomes (operative time, transfusion, SSI, LOS, readmissions) and functional measures (swallowing, speech) to identify approaches that maintain oncologic control while minimizing resource use. Payers and hospital teams use this evidence to guide choices that balance clinical effectiveness with costs and to standardize pathways that reduce variability in reimbursement for DRG 148 admissions.
Post-discharge survivorship and complications/outcomes cohorts tracking late effects and health service use after uncomplicated inpatient treatment: longitudinal observational studies follow patients who had ear, nose, mouth, and throat malignancies treated without major complications to capture rates of late functional impairment, ostomy or feeding tube dependence, secondary procedures, outpatient therapy needs, and unplanned readmissions. These studies clarify long-term quality-of-life trajectories and cumulative healthcare utilization for a population initially classified as DRG 148, informing follow-up care standards, rehabilitation referral timing, and payer projections of downstream costs beyond the index hospitalization.

Neoadjuvant and perioperative therapy trials assessing the impact of chemotherapy and/or radiation given before definitive surgery: these studies enroll patients with operable head and neck squamous cell carcinomas of the ear, nose, mouth, and throat who are scheduled for tumor resection and neck dissection. Investigators measure tumor downstaging, margin status, rates of organ-preserving surgery, and perioperative complication rates to determine whether preoperative therapy improves surgical outcomes. Results are relevant to providers and payers because improved downstaging can reduce extent of surgery, length of stay, and downstream costs associated with extensive reconstructions and complications.
Comparative effectiveness studies of surgical approaches and perioperative management for primary resection without major complications: these pragmatic trials or registry analyses compare techniques such as transoral robotic or endoscopic resections versus open approaches, different reconstruction strategies, and enhanced recovery after surgery (ERAS) protocols in patients without major comorbidities. They focus on short-term inpatient outcomes (operative time, transfusion, SSI, LOS, readmissions) and functional measures (swallowing, speech) to identify approaches that maintain oncologic control while minimizing resource use. Payers and hospital teams use this evidence to guide choices that balance clinical effectiveness with costs and to standardize pathways that reduce variability in reimbursement for DRG 148 admissions.
Post-discharge survivorship and complications/outcomes cohorts tracking late effects and health service use after uncomplicated inpatient treatment: longitudinal observational studies follow patients who had ear, nose, mouth, and throat malignancies treated without major complications to capture rates of late functional impairment, ostomy or feeding tube dependence, secondary procedures, outpatient therapy needs, and unplanned readmissions. These studies clarify long-term quality-of-life trajectories and cumulative healthcare utilization for a population initially classified as DRG 148, informing follow-up care standards, rehabilitation referral timing, and payer projections of downstream costs beyond the index hospitalization.

OpenPayer

Summary & Overview

Ear, Nose, Mouth and Throat Malignancy without CC/MCC: Inpatient Reimbursement Overview

DRG 148 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes